What is the efficacy of osimertinib in T790 patients?

Osimertinib has significant efficacy in patients with T790M mutation. Osimertinib is a targeted drug for lung cancer. It is particularly suitable for adult patients with locally advanced or metastatic non-small cell lung cancer whose disease has progressed during or after treatment with epidermal growth factor receptor tyrosine kinase inhibitors and whose EGFRT790M mutation-positive disease has been confirmed by testing.

Osimertinib is a kinase inhibitor of epidermal growth factor receptor(EGFR). The concentration of irreversible binding to certain mutants of EGFR is about 9 times lower than that of the wild type. This specific binding allows osimertinib to act precisely on cancer cells carrying EGFR mutations, thereby exerting anti-tumor effects.

According to the results of multiple clinical trials, osimertinib performed well in treating patients with T790M mutation-positive non-small cell lung cancer. For example, in a clinical trial, osimertinib showed significant efficacy in T790M mutation-positive patients who had previously received first-generation/second-generation EGFR-TKI treatment and had disease progression. The disease of these patients has been effectively controlled and their quality of life has been significantly improved.

Although some adverse reactions may occur during the use of osimertinib, such as skin problems, digestive system symptoms, respiratory complications, and cardiovascular system problems, most patients are able to tolerate these reactions and can be adjusted and managed under the guidance of a doctor.

For patients with first- or second-generation EGFR-TKI resistance, especially those with negative T790M mutation, osimertinib has also shown certain efficacy. Clinical trials have shown that osimertinib can produce a certain objective response rate even in patients who are negative for T790M, providing a new treatment option for these patients.